Powderly, J., G. Cote, K. Flaherty, R. Z. Szmulewitz, A. Ribas, J. Weber, D. Loo, et al. 2015. “Interim results of an ongoing Phase I, dose escalation study of MGA271 (Fc-optimized humanized anti-B7-H3 monoclonal antibody) in patients with refractory B7-H3-expressing neoplasms or neoplasms whose vasculature expresses B7-H3.” Journal for Immunotherapy of Cancer 3 (Suppl 2): O8. doi:10.1186/2051-1426-3-S2-O8. http://dx.doi.org/10.1186/2051-1426-3-S2-O8.